[
  {
    "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Therefore, this review focus on the current update on therapeutics challenges in managing neuroblastoma, specifically overcoming the BBB and application of nanoparticles technology for vaccine delivery.Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Neuroblastoma: focus and challenges\nNeuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "For instance, children diagnosed with localized neuroblastoma have a chance of 90% surviving, whereas, for patients with stage 4 neuroblastoma, the survival rate is much lower, ranging between 40% and 50%.14,16\n\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Neuroblastoma is a type of cancer particularly found in children originating from neuroblasts or the cells in the development of the sympathetic nervous system, as shown in Figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Since the immune system is selective for tumor cells, some immunotherapeutic agents can increase BBB permeability selectively as seen in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]